Shanghai Henlius Biotech announced that China’s National Medical Products Administration accepted investigational new drug (IND) applications for three differentiated solid‑tumor candidates. The IND clearances permit the company to initiate clinical development in China and expand its oncology portfolio into additional tumor types. Henlius described the candidates as differentiated biologics engineered for solid‑tumor targeting; the filings reflect China’s ongoing push to accelerate domestic oncology pipelines. Observers will monitor trial start timelines and potential global development plans from the company.